Abstract not available at this time.
This paper describes methods used in the project “Orofacial Pain Prospective Evaluation and Risk Assessment” (OPPERA) and evaluates sociodemographic characteristics associated with temporomandibular disorders (TMD) in the OPPERA case-control study. Representativeness was investigated by comparing sociodemographic profiles of OPPERA participants with population census profiles of counties near study sites and by comparing age and gender associations with TMD in OPPERA and the 2007 to 2009 US National Health Interview Survey.
Automated clinical databases are an important data source for drug utilization studies but often they do not capture prescriptions for drugs such as biological agents and other data sources are required. We describe how a feasibility evaluation (FE) was designed and implemented for a drug utilization study (DUS) of RTX, a biological agent approved for the treatment of rheumatoid arthritis, granulomatosis with polyangiitis and microscopic polyangiitis, and administered in specialized infusion centers (ICs). There is some evidence of RTX use in additional conditions, e.g.
Objective: The impact of migraines on patients is commonly divided between the level of impairment associated with headache symptoms (headache phase) and the quality-of-life effects immediately following the headache (post-headache phase). Evaluations of migraineurs' productivity losses and health-related quality of life have provided an understanding of the burden associated with the headache and post-headache symptoms, but do not quantify the relative importance of each phase from a patient perspective.
Patients with myelofibrosis (MF) have significant debilitating symptoms, physical disabilities, and poor health-related quality of life (HRQoL). Here, we report post-hoc analyses of the impact of ruxolitinib, a potent and selective JAK1 and JAK2 inhibitor, on disease-related symptoms and HRQoL in MF patients from the large phase 3 COMFORT-II study (N = 219). During the follow-up period of 48 weeks, HRQoL and MF-associated symptoms improved from baseline for ruxolitinib-treated patients but remained the same or worsened for best available therapy (BAT)-treated patients.
OBJECTIVES: Treatment of acute pain often includes use of nonsteroidal anti-inflammatory drugs (NSAIDs). Although effective, they are known to cause adverse events (AEs), including gastrointestinal, cardiovascular, and renal events.
We conducted a review of patient medical records to assess treatment response patterns and prognostic indicators of response among chronic myeloid leukemia (CML) patients in the United States, the United Kingdom, Germany, and Japan. All 1,063 patients selected met the following inclusion criteria: aged 18 or older and in chronic phase at the time of diagnosis, Philadelphia chromosome and/or BCR-ABL positive, received first-line treatment with imatinib, and not enrolled in a randomized clinical trial during the period of retrospective review.
OBJECTIVES: To examine patient and disease characteristics and treatment patterns among patients with chronic myeloid leukemia (CML) in multiple countries.
METHODS: Oncologists and hematologists in the United States (US), UK (UK), Germany, and Japan abstracted medical charts of adult patients with CML between January 1, 2005 and December 31, 2009. Patients were in chronic phase at diagnosis, either Ph or BCR-ABL positive, had received first line treatment with imatinib, and had not participated in a randomized clinical trial for CML.
OBJECTIVE: The aims of this report are to quantify and compare competing risks associated with the use of non-prescription analgesics (daily doses of acetaminophen ≤ 4000 mg, aspirin ≤ 4000 mg, ibuprofen ≤ 1200 mg, naproxen ≤ 660 mg and ketoprofen ≤ 75 mg) and identify research needs.
METHODS: Literature was searched and organized by medication, adverse effect and direction of effect. Causality was determined using structured consensus, using IOM and GRADE nomenclature.
OBJECTIVES: OROS hydromorphone (osmotic extended-release oral delivery system [OROS] hydromorphone) is a long-acting opioid analgesic, which is approved in Europe for the management of severe pain. The authors aimed to estimate the economic value of this product relative to other widely used oral opioids, including sustained-release morphine, extended-release (ER) oxycodone, and twice-daily (bid) hydromorphone.
DESIGN: An adaptable, decision-analytic cost-utility model was developed.